AT1 Shares Atomo Diagnostics Limited
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Point-of-care diagnostics adoption could improve revenue trajectory from a heavily discounted base.
Signal breakdown
- ▸Commercial rollout remains the principal near-term catalyst.
- ▾Below 50-day MA (-4.23%)
- ▾Near 52-week low (3.1% of range)
Is AT1 a buy right now?
Trend: AT1 is trading below the 50-day average (-15.00%), RSI 48 — neutral momentum, with a 3-month return of -2.86%.
Valuation & quality: Atomo Diagnostics Limited trades on price-to-book 1.89; fundamentals show net margin -65.9%, return on equity -47.9%, revenue growth 81.2% year on year.
Our screen: WATCH (score 0) — Point-of-care diagnostics adoption could improve revenue trajectory from a heavily discounted base.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.00% | -33.30% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Atomo Diagnostics Limited
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions.
Sector: Healthcare · Industry: Medical Devices · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.